论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu D, Wang D, Wu C, Zhang L, Mei Q, Hu G, Long G, Sun W
Received 22 December 2018
Accepted for publication 21 March 2019
Published 26 April 2019 Volume 2019:11 Pages 3611—3619
DOI https://doi.org/10.2147/CMAR.S199260
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Background: Multiple
studies have assessed the prognostic significance of serum lactate
dehydrogenase (LDH) in patients with breast cancer, but their results remain
controversial. This study aimed to evaluate the prognostic value of LDH in
breast cancer by meta-analysis.
Methods: Electronic
searches for relevant articles were conducted in PubMed, Embase and Web of
Science databases. The HR and their 95% CI were used to assess the prognostic
value of serum LDH. Stata Statistical Software 12.0 was applied for statistical
analysis.
Results: A total
of 11 studies involving 6,102 patients were subjected to final analysis. Our
results showed that higher serum LDH had significant effect on poor overall
survival (HR, 1.88; 95% CI, 1.68–2.11) and progression-free survival (HR, 1.98;
95% CI, 1.46–2.68). Moreover, the results of subgroup analyses were consistent
with that of overall outcomes. No significant heterogeneity and publication
bias were found in this study.
Conclusion: Serum LDH
could act as a prognostic factor for patients with breast cancer. Future data
are needed to validate and update our results.
Keywords: breast
cancer, lactate dehydrogenase, prognosis, biomarker, meta-analysis
